Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy? - Wikidata - awgldk - TriplyDB

Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?

Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?

http://www.wikidata.org/entity/Q24803763

about

Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?

http://www.wikidata.org/entity/Q24803763

description

2004 nî lūn-bûn

@nan

2004 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Optimizing complement-activati ...... otherapy: a feasible strategy?

@ast

Optimizing complement-activati ...... otherapy: a feasible strategy?

@en

Optimizing complement-activati ...... otherapy: a feasible strategy?

@nl

type

label

Optimizing complement-activati ...... otherapy: a feasible strategy?

@ast

Optimizing complement-activati ...... otherapy: a feasible strategy?

@en

Optimizing complement-activati ...... otherapy: a feasible strategy?

@nl

prefLabel

Optimizing complement-activati ...... otherapy: a feasible strategy?

@ast

Optimizing complement-activati ...... otherapy: a feasible strategy?

@en

Optimizing complement-activati ...... otherapy: a feasible strategy?

@nl

P1433

Q24803763-44EC8038-2D89-40D6-9B98-7EE8D3BD1886

P1476

Q24803763-5896AFC7-1EAF-4903-AC89-62B062F10B6D

P2093

Q24803763-5CE5992A-62DA-40C6-A982-5E0932B412A4

Q24803763-94E07244-80C5-445F-81B4-59D55A8EE32B

Q24803763-F3FE05C6-9DD5-473D-B922-59D949A79F6A

P2860

Q24803763-036E7A97-281E-4722-BC6B-4A33B307F6F7

Q24803763-0F4A4BEB-FAD0-4E4F-AEE0-E8AA1FB972EA

Q24803763-1078AE9C-0DA3-4849-A768-DCB00D94EBF1

Q24803763-49EF6B95-CD76-4C00-BC44-92785A814CC3

Q24803763-4BF67836-3D5B-47BA-B765-160D9421341B

Q24803763-54F80EC0-1261-4EBD-AD75-F4A30B3FDE3C

Q24803763-7AF3752C-AB31-41F3-B216-D277031ED356

Q24803763-8F223EF4-C0D1-4F73-8BF4-A1827BB17A75

Q24803763-BCE336FA-0564-493D-A22E-4F3AE15D4EA6

Q24803763-BE45F8C7-A1EB-45DA-9EF6-A203647B0E2E

P2888

Q24803763-9E3BF194-4A00-4A24-945A-BF94B3986BE7

P304

Q24803763-E06F03BC-E5CA-4977-881E-E7744698EC0B

P31

Q24803763-6A63647C-E6C4-47D4-BB4E-18003CDBE175

P356

Q24803763-4EB75FB2-B01C-438E-926D-B7DBDC8F944E

P433

Q24803763-EA83BF55-3198-4C6F-9C15-2CF8800B4E24

P478

Q24803763-CAB098B7-7749-4FA9-97C9-52FF5F8A5942

P577

Q24803763-1CE3EE65-C5CA-45DF-91E8-2A933B18BF67

P5875

Q24803763-1D843089-01D6-476B-916C-CCE3C3776C74

P6179

Q24803763-ABBBB9DA-D91E-40BB-B242-BC542048B0A6

P698

Q24803763-BB4A7108-2B5D-4641-A00B-38221219EDF2

P921

Q24803763-EC6336C5-D223-4AC8-9450-E1D626328C50

P932

Q24803763-8C4692CC-9416-4AD9-87EA-7B57B5873C61

P356

P1433

Journal of Translational Medicine

P1476

Optimizing complement-activati ...... otherapy: a feasible strategy?

@en

P2093

Anna Maria Di Giacomo

http://www.w3.org/2001/XMLSchema#string

Ester Fonsatti

http://www.w3.org/2001/XMLSchema#string

Michele Maio

http://www.w3.org/2001/XMLSchema#string

P2860

CD59 is physically and functionally associated with natural cytotoxicity receptors and activates human NK cell-mediated cytotoxicity

Structure, distribution, and functional role of protectin (CD59) in complement-susceptibility and in immunotherapy of human malignancies (Review)

Physiologic relevance of the membrane attack complex inhibitory protein CD59 in human seminal plasma: CD59 is present on extracellular organelles (prostasomes), binds cell membranes, and inhibits complement-mediated lysis

Complement function in mAb-mediated cancer immunotherapy.

Monoclonal antibodies as therapeutic agents for cancer.

Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity.

Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2.

Expression and function of CD59 on colonic adenocarcinoma cells.

Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial.

Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies.

P2888

P304

21

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1479-5876-2-21

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2004-06-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8489558

http://www.w3.org/2001/XMLSchema#string

P6179

1000143120

http://www.w3.org/2001/XMLSchema#string

P698

15219237

http://www.w3.org/2001/XMLSchema#string

P921

P932

455694

http://www.w3.org/2001/XMLSchema#string